Inside Nouscom

VIEW ALL

Cancer vaccines come of age

Our strategy stems from recent therapeutic achievements in the fields of checkpoint inhibitors, therapeutic antibodies, cancer vaccines and oncolytic viruses. We plan to develop a series of new, potent immunotherapeutics capable of selectively killing tumor cells. Our immunotherapeutics embody the best features of oncolytic viruses and therapeutic antibodies, and include viral vectored genetic vaccines based on patient- and tumor-specific antigens.

Read more
  • Nouscom Appoints New Chief Operating Officer and Strengthens the Board of Directors

    Read more
  • Sept 27. – Nouscom presents at the Sachs 16th Annual Biotech in Europe forum

    Read more
  • Nouscom concludes successful series A financing of EUR 12 million

    Read more